Morgan Stanley set a CHF 290 price objective on Roche Holding Ltd. (VTX:ROG) in a research report report published on Tuesday. The brokerage currently has a buy rating on the healthcare company’s stock.

ROG has been the topic of a number of other reports. Deutsche Bank AG set a CHF 273 target price on Roche Holding and gave the stock a buy rating in a research report on Tuesday, June 6th. Barclays PLC set a CHF 320 price target on Roche Holding and gave the stock a buy rating in a report on Saturday, May 20th. J P Morgan Chase & Co reiterated a buy rating on shares of Roche Holding in a report on Wednesday, April 5th. Citigroup Inc. reiterated a buy rating on shares of Roche Holding in a report on Wednesday, July 5th. Finally, Kepler Capital Markets set a CHF 231 price target on Roche Holding and gave the stock a neutral rating in a report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of CHF 272.50.

Roche Holding (VTX:ROG) opened at 246.20 on Tuesday. Roche Holding has a 1-year low of CHK 218.30 and a 1-year high of CHK 273.00. The company has a market capitalization of CHK 209.75 billion and a PE ratio of 21.13. The company has a 50 day moving average of CHK 259.00 and a 200 day moving average of CHK 249.75.

ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/morgan-stanley-analysts-give-roche-holding-ltd-vtxrog-a-chf-290-price-target/1443349.html.

About Roche Holding

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche Holding (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.